| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1681/ASN.2007010073 |
| P698 | PubMed publication ID | 17360947 |
| P2093 | author name string | Robert B Colvin | |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1046-1056 | |
| P577 | publication date | 2007-03-14 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Antibody-mediated renal allograft rejection: diagnosis and pathogenesis | |
| P478 | volume | 18 |
| Q46360525 | 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection |
| Q26992169 | A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury |
| Q36887068 | A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody |
| Q39470034 | A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection |
| Q38211716 | A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection |
| Q46208009 | Absence of C4d urinary excretion in the early post-transplant period is associated with improved long-term kidney graft survival |
| Q37236857 | Accommodation in organ transplantation |
| Q38445336 | Achieving incompatible transplantation through desensitization: current perspectives and future directions |
| Q40108113 | Acute Cellular Rejection and C4d Positivity in Heart Transplantation : A Manifestation of Asymptomatic Antibody-Mediated Rejection? |
| Q36872090 | Acute antibody-mediated rejection following heart transplantation |
| Q83774038 | Acute antibody-mediated rejection in paediatric renal transplant recipients |
| Q37807572 | Adding Value to Liver (and Allograft) Biopsy Evaluation Using a Combination of Multiplex Quantum Dot Immunostaining, High-Resolution Whole-Slide Digital Imaging, and Automated Image Analysis |
| Q37686066 | Advances in immunosuppression for renal transplantation. |
| Q33414342 | An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies |
| Q39737548 | Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies |
| Q34667057 | Antibodies in transplantation |
| Q41849097 | Antibodies in transplantation: the effects of HLA and non-HLA antibody binding and mechanisms of injury. |
| Q51278545 | Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies? |
| Q37904197 | Antibody-mediated allograft rejection: the emerging role of endothelial cell signalling and transcription factors. |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q36666906 | Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation |
| Q84409945 | Antibody-mediated response in rat liver chronic rejection |
| Q86859069 | Antibody-mediated vascular rejection of kidney allografts: a population-based study |
| Q44468613 | Antibody-mediated vascular rejection: relation to causation |
| Q85159536 | Antihuman Leukocyte Antigen–Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches |
| Q53504304 | Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. |
| Q37832966 | Assessment of kidney organ quality and prediction of outcome at time of transplantation |
| Q93562475 | Authors' reply |
| Q50870575 | B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody-mediated rejection. |
| Q58836868 | B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection |
| Q44180277 | Banff initiative for quality assurance in transplantation (BIFQUIT): reproducibility of C4d immunohistochemistry in kidney allografts |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q41577805 | Benefits, efficacy, cost-effectiveness and infectious complications in transplant patients desensitized with intravenous immunoglobulin and anti-CD20 therapy |
| Q38390676 | Blood Vessels in Allotransplantation |
| Q33584895 | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial |
| Q40417954 | C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study |
| Q61796443 | C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro |
| Q90023517 | C3d-binding Donor-specific HLA Antibody Is Associated With a High Risk of Antibody-mediated Rejection and Graft Loss in Stable Kidney Transplant Recipients: A Single-center Cohort Study |
| Q84556573 | C4D immunostaining in surveillance endomyocardial biopsies from well-functioning heart allografts |
| Q41944673 | C4d staining in allograft biopsies |
| Q47571875 | C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies |
| Q37704862 | Capillary dilation and rarefaction are correlated with intracapillary inflammation in antibody-mediated rejection. |
| Q37247572 | Chronic Humoral Rejection of Human Kidney Allografts Is Associated with MMP-2 Accumulation in Podocytes and its Release in the Urine |
| Q37058050 | Chronic alloantibody mediated rejection |
| Q37394650 | Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses |
| Q45681850 | Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss |
| Q38163419 | Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis |
| Q41758257 | Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. |
| Q82092406 | Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney |
| Q37367683 | Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. |
| Q33419693 | Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy |
| Q82887852 | Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis |
| Q26829790 | Complement cascade and kidney transplantation: The rediscovery of an ancient enemy |
| Q35001174 | Complement in organ transplantation. |
| Q37667779 | Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. |
| Q38772141 | Contributions of direct and indirect alloresponses to chronic rejection of kidney allografts in nonhuman primates |
| Q51744862 | Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. |
| Q41514316 | Correlation of Pretransplant Donor-specific Antibody Assay Using Luminex Crossmatch with Graft Outcome in Renal Transplant Patients |
| Q58610900 | Critical Role of Macrophage FcγR Signaling and Reactive Oxygen Species in Alloantibody-Mediated Hepatocyte Rejection |
| Q50548088 | DRβ1*1501, DQβ1*0602 donor allelic haplotype and humoral antibody episodes of acute renal allograft rejection. |
| Q30403833 | De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients |
| Q39615715 | Decreased humoral antibody episodes of acute renal allograft rejection in recipients expressing the HLA-DQβ1*0202 allele |
| Q35940388 | Depression of Complement Regulatory Factors in Rat and Human Renal Grafts Is Associated with the Progress of Acute T-Cell Mediated Rejection. |
| Q35995043 | Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients |
| Q40373480 | Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study. |
| Q38168293 | Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation |
| Q35027253 | Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. |
| Q43874614 | Detection of C4d-fixing HLA antibodies in serum - a glass half full and half empty |
| Q38204851 | Detection of donor-specific antibodies in kidney transplantation |
| Q34224452 | Diagnosis and prevention of chronic kidney allograft loss |
| Q46045914 | Diagnosis and treatment of acute humoral kidney allograft rejection. |
| Q85635101 | Diagnosis and treatment of antibody mediated rejection in lung transplantation: a retrospective case series |
| Q53361163 | Differential deposition of C4d and MBL in glomeruli of patients with ANCA-negative pauci-immune crescentic glomerulonephritis. |
| Q42738129 | Dimensions of antibody-mediated rejection |
| Q34839515 | Diminished met signaling in podocytes contributes to the development of podocytopenia in transplant glomerulopathy |
| Q26863724 | Direct and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney Transplantation |
| Q45106203 | Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies |
| Q42111937 | Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. |
| Q41899266 | Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants |
| Q35668667 | Effectiveness of Intravenous Immunoglobulin Plus Plasmapheresis on Antibody-mediated Rejection or Thrombotic Microangiopathy in Iranian Kidney Transplant Recipient |
| Q56908066 | Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study |
| Q35124576 | Emerging role of B cells in chronic allograft dysfunction |
| Q40806353 | Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants |
| Q50582511 | Endothelial injury in transplant glomerulopathy is correlated with transcription factor T-bet expression. |
| Q59800451 | Endothelium in the allograft |
| Q35021857 | Experimental glomerular endothelial injury in vivo |
| Q24654702 | Expression of complement components differs between kidney allografts from living and deceased donors |
| Q37112977 | Fc gamma RIII and Fc gamma RIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies |
| Q27026499 | Flow cytometry and solid organ transplantation: a perfect match |
| Q37315152 | Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival |
| Q34534928 | Genotypic diversity of complement component C4 does not predict kidney transplant outcome |
| Q58004250 | Glomerular C4d Immunoreactivity in Acute Rejection Biopsies of Renal Transplant Patients |
| Q36800330 | Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria |
| Q33392769 | Glomerular fibrin thrombi in ABO and crossmatch compatible renal allograft biopsies |
| Q89425395 | HLA and lung transplantation |
| Q37383181 | Hematopoietic Stem Cell Transplantation Nephropathy Associated with Chronic Graft-versus-Host Disease without Extrarenal Involvement. |
| Q36024233 | Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance |
| Q34289043 | Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions |
| Q37964421 | Immunology of uterine transplantation: a review |
| Q99413307 | Immunosuppression in uterine transplantation |
| Q49297064 | Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection |
| Q46897107 | Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations |
| Q47747221 | Impact of donor ABH-secretor status in ABO-mismatched living donor kidney transplantation. |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q90024229 | In the absence of natural killer cell activation donor-specific antibody mediates chronic, but not acute, kidney allograft rejection |
| Q53603593 | Influence of de novo donor-specific antibody on early renal allograft function recovery. |
| Q46963752 | Influence of preformed donor-specific antibodies and C4d on early liver allograft function |
| Q89013970 | Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis |
| Q48160896 | Is pre-transplant sensitization against angiotensin II type 1 receptor still a risk factor of graft and patient outcome in kidney transplantation in the anti-HLA Luminex era? A retrospective study. |
| Q27023312 | Issues in solid-organ transplantation in children: translational research from bench to bedside. |
| Q34024926 | Key role for CD4 T cells during mixed antibody-mediated rejection of renal allografts |
| Q52310243 | Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. |
| Q38658621 | Kidney transplantation, bioengineering and regeneration: an originally immunology-based discipline destined to transition towards ad hoc organ manufacturing and repair. |
| Q87252731 | Kidney transplantation: evaluation and clinical outcome of 237 recipients at low, medium, high, or strong immunological risk of rejection |
| Q50910367 | Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection. |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q53782591 | Living-donor kidney transplantation with existing anti-donor specific antibodies at a Japanese single center. |
| Q47272995 | Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules |
| Q43848201 | Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation |
| Q40149564 | Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. |
| Q46356692 | Maintenance immunosuppressive therapy in adult renal transplantation: a single center analysis. |
| Q38597010 | Mechanisms underlying human genetic diversity: consequence for anti-graft antibody responses. |
| Q42722907 | Memory CD4 T Cells Induce Antibody-Mediated Rejection of Renal Allografts |
| Q57202180 | Modulation of Innate Immune Cells to Create Transplant Tolerance |
| Q33711255 | Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. |
| Q38773711 | Moving Biomarkers toward Clinical Implementation in Kidney Transplantation |
| Q42784445 | Natural killer cells play a critical role in mediating inflammation and graft failure during antibody-mediated rejection of kidney allografts |
| Q60916304 | Non-invasive Biomarkers of Acute Rejection in Kidney Transplantation: Novel Targets and Strategies |
| Q42247863 | Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation |
| Q46258296 | Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection |
| Q33395896 | Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy |
| Q36529421 | Pathological diagnosis of antibody-mediated rejection in renal allograft without c4d staining, how much reliable? |
| Q44458696 | Pediatric kidney recipients may benefit from monitoring for donor-specific antibodies |
| Q44608227 | Peritubular capillaritis in early renal allograft dysfunction is an indicator of acute rejection |
| Q53033816 | Peritubular capillaritis in renal allografts: prevalence, scoring system, reproducibility and clinicopathological correlates. |
| Q37394636 | Polyreactive antibodies developing amidst humoral rejection of human kidney grafts bind apoptotic cells and activate complement. |
| Q30421507 | Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. |
| Q40159121 | Postanastomotic transplant renal artery stenosis: association with de novo class II donor-specific antibodies. |
| Q59314345 | Precision Diagnostics in Transplantation: From Bench to Bedside |
| Q38019584 | Prediction of organ transplant rejection by HLA-specific and non-HLA antibodies--brief literature review |
| Q34534855 | Predominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection |
| Q50722278 | Preformed circulating HLA-specific memory B cells predict high risk of humoral rejection in kidney transplantation. |
| Q33998148 | Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. |
| Q43817587 | Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss |
| Q26751478 | Proteomics for rejection diagnosis in renal transplant patients: Where are we now? |
| Q36173541 | Rational clinical trial design for antibody mediated renal allograft injury. |
| Q37301840 | Recent developments in kidney transplantation--a critical assessment |
| Q37877263 | Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation |
| Q38120752 | Regulatory T cells in the immunodiagnosis and outcome of kidney allograft rejection |
| Q43133854 | Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients |
| Q38027504 | Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation. |
| Q54998259 | Renal Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation: Involvement of Chronic Graft-Versus-Host Disease. |
| Q38709765 | Renal allograft pathology with C4d immunostaining in patients with graft dysfunction |
| Q34746617 | Renal and urinary levels of endothelial protein C receptor correlate with acute renal allograft rejection |
| Q33407913 | Renal arteriolar C4d deposition: a novel characteristic of hematopoietic stem cell transplantation-associated thrombotic microangiopathy |
| Q33396969 | Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. |
| Q38967258 | Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement |
| Q43116256 | Renal transplantation across ABO barrier. |
| Q58048128 | Repeat A2 into B kidney transplantation after failed prior A2 into B transplant: A Case Report |
| Q37231896 | Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig |
| Q42138480 | Role of T cell TGFbeta signaling and IL-17 in allograft acceptance and fibrosis associated with chronic rejection |
| Q26864255 | Role of complement and NK cells in antibody mediated rejection |
| Q37966037 | Role of microRNAs in immunity and organ transplantation. |
| Q34218928 | Scleroderma Renal Crisis: A Pathology Perspective |
| Q51043732 | Sequential analysis of donor-specific antibodies and pathological findings in acute antibody-mediated rejection in a rat renal transplantation model. |
| Q83102265 | Serial monitoring of humoral antibody-mediated rejection of cardiac allografts by C4d staining of interstitial capillaries |
| Q50955240 | Soluble BAFF Cytokine Levels and Antibody-Mediated Rejection of the Kidney Allograft. |
| Q43466537 | Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft |
| Q33873078 | T-cell co-stimulatory blockade in kidney transplantation: back to the bench |
| Q38148197 | T-cell co-stimulatory blockade in transplantation: two steps forward one step back! |
| Q38878037 | Tac-MMF Versus CsA-MMF/CsA-AZA-Based Regimens in Development of De Novo Complement-Binding Anti-HLA Antibodies After Kidney Transplantation. |
| Q28087773 | The Complement System and Antibody-Mediated Transplant Rejection |
| Q54962211 | The Kinetics of Anti-HLA Antibodies in the First Year after Kidney Transplantation: In Whom and When Should They Be Monitored? |
| Q42233729 | The Presence of Anti-Angiotensin II Type-1 Receptor Antibodies Adversely Affect Kidney Graft Outcomes. |
| Q37359074 | The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy |
| Q36719246 | The clinical impact of humoral immunity in pediatric renal transplantation. |
| Q37286247 | The diagnostic value of transcription factors T-bet/GATA3 ratio in predicting antibody-mediated rejection. |
| Q47849640 | The effect of glutathion S-transferase polymoprhisms and anti-GSTT1 antibodies on allograft functions in recipients of renal transplant |
| Q34106158 | The generation and maintenance of serum alloantibody. |
| Q38003049 | The impact of donor-specific anti-HLA antibodies on late kidney allograft failure |
| Q27021227 | The importance of C4d in biopsies of kidney transplant recipients |
| Q37813404 | The pathology of chronic allograft dysfunction |
| Q43241187 | The prevalence of C4d-positive renal allografts in 134 consecutive biopsies in Thai patients |
| Q38013049 | The role of complement in the early immune response to transplantation. |
| Q84522326 | The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy |
| Q38151921 | The specificity of acute and chronic microvascular alterations in renal allografts |
| Q33406570 | The use of eculizumab in renal transplantation |
| Q40745610 | Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients |
| Q43507137 | Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negative patients |
| Q21999478 | Transplant biopsy beyond light microscopy |
| Q37092282 | Transplant glomerulopathy |
| Q38205229 | Transplant glomerulopathy: the interaction of HLA antibodies and endothelium |
| Q54349986 | Transplantation: CNIs to mTOR inhibitors--effects on allosensitization? |
| Q86094428 | Transplantation: Donor-specific HLA antibodies and renal allograft failure |
| Q37677980 | Transplantology: Challenges for Today |
| Q36677655 | Tribbles-1 as a novel biomarker of chronic antibody-mediated rejection. |
| Q37052024 | Tubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific Antibodies |
| Q42281859 | Upregulation of microRNA 142-3p in the peripheral blood and urinary cells of kidney transplant recipients with post-transplant graft dysfunction |
| Q36223302 | Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection |
| Q37852766 | Uterine transplantation: a promising surrogate to surrogacy? |
| Q93074073 | WITHDRAWN: [Non anti-HLA antibodies and acute rejection: A critical viewpoint] |
| Q82564747 | [Role of anti-HLA antibodies whether or not they are directed against the donor during chronic renal graft dysfunction] |
Search more.